ACT-541468 + citalopram

**ACT-541468 + citalopram** is a combination of two pharmaceutical drugs: daridorexant (code name ACT-541468), a dual orexin receptor antagonist being developed for the treatment of insomnia, and citalopram, a selective serotonin reuptake inhibitor (SSRI) widely approved for the treatment of major depressive disorder and other psychiatric conditions. Daridorexant promotes sleep via antagonism of orexin receptors OX1R and OX2R, which regulate wakefulness, while citalopram increases serotonin activity in the CNS by inhibiting its reuptake, thereby exerting antidepressant and anxiolytic effects. Co-administration is under clinical evaluation for pharmacokinetic and pharmacodynamic safety and tolerability in healthy individuals, with minor interaction effects and safety confirmed for doses up to 50 mg daridorexant with citalopram[1][3].

Other names

daridorexantcitalopram